[
    [
        {
            "time": "2018-03-15",
            "original_text": "Why You Should Buy ABBV Stock for Income and Value",
            "features": {
                "keywords": [
                    "ABBV",
                    "Buy",
                    "Income",
                    "Value"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Why You Should Buy ABBV Stock for Income and Value",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-04-20",
            "original_text": "Abbott's (ABT) MitraClip COAPT Trial Shows Favorable Results",
            "features": {
                "keywords": [
                    "Abbott",
                    "ABT",
                    "MitraClip",
                    "COAPT",
                    "Trial",
                    "Favorable",
                    "Results"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Abbott's (ABT) MitraClip COAPT Trial Shows Favorable Results",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-05-10",
            "original_text": "What Makes Abbott (ABT) a New Buy Stock",
            "features": {
                "keywords": [
                    "Abbott",
                    "ABT",
                    "New",
                    "Buy",
                    "Stock"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "What Makes Abbott (ABT) a New Buy Stock",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-06-25",
            "original_text": "3 Blue Chip Stocks That Just Hit 52-Week Highs: Are They Buys?",
            "features": {
                "keywords": [
                    "Blue Chip",
                    "Stocks",
                    "52-Week Highs",
                    "Buys"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "general"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "3 Blue Chip Stocks That Just Hit 52-Week Highs: Are They Buys?",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-07-12",
            "original_text": "Abbott Announces CE Mark for Alinity™ m Diagnostics System and Assays, the Latest in Molecular Technology, to Help Deliver Critical Test Results and Benefits to Patients",
            "features": {
                "keywords": [
                    "Abbott",
                    "CE Mark",
                    "Alinity",
                    "Diagnostics",
                    "Molecular Technology",
                    "Test Results",
                    "Benefits",
                    "Patients"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Abbott Announces CE Mark for Alinity™ m Diagnostics System and Assays, the Latest in Molecular Technology, to Help Deliver Critical Test Results and Benefits to Patients",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-08-15",
            "original_text": "3 Blue-Chip Stocks That Just Hit 52-Week Highs: Are They Buys?",
            "features": {
                "keywords": [
                    "Blue-Chip",
                    "Stocks",
                    "52-Week Highs",
                    "Buys"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "general"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "3 Blue-Chip Stocks That Just Hit 52-Week Highs: Are They Buys?",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        }
    ]
]